Everything below concerns angiotensin IV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
== Use and effects == The properties and effects of muscimol in humans have been limitedly assessed in clinical studies. It has been assessed in these studies at doses of 5 to 15 mg orally. The oral threshold dose of muscimol is approximately 6 mg, while the psychoactive dose range has been said to range from approximately 8 to 15 mg. As little as 1 g of dried Amanita muscaria button may contain this amount of muscimol, although the potency varies greatly among mushrooms. According to Jonathan Ott, a 15 mg dose is "psychoptic" while a 20 mg dose is "visionary". The onset of action of muscimol, via isolated muscimol or Amanita muscaria consumption orally, is between 30 minutes and 2 hours, with peak effects occurring after 1 to 3 hours. The duration is 4 to 10 hours, but some effects may persist for up to 24 hours. In one publication, the effects of muscimol were described as follows:
=== 23 January === Polish Prime Minister Mateusz Morawiecki stated that Poland will provide 14 Leopard tanks to Ukraine regardless of Germany's approval; the next day, Poland officially requested permission to export them. German Defence Minister Boris Pistorius encouraged other countries to provide training on the tanks for Ukrainian soldiers. French President Emmanuel Macron stated that France would send Leclerc tanks to Ukraine. Norwegian defence chief General Eirik Kristoffersen stated that around 180,000 Russian soldiers were dead or wounded and there were around 100,000 military casualties and 30,000 civilian dead from Ukraine.
== Names == Alternative terms for low level light therapy are: LLLT, laser biostimulation, laser phototherapy, low-level laser therapy, low-power laser irradiation, low-power laser therapy, and photobiomodulation therapy. The term photobiomodulation therapy is considered the preferred term by industry professionals. However LLLT has been marketed and researched under a number of other terms, including red light therapy, low-power laser therapy (LPLT), soft laser therapy, low-intensity laser therapy, low-energy laser therapy, cold laser therapy, bio-stimulation laser therapy, photo-biotherapy, therapeutic laser, and monochromatic infrared light energy (MIRE) therapy. More specific applications sometimes have their own terms, for example when administered to acupuncture points, the procedure is called laser acupuncture. When applied to the head, LLLT may be known as transcranial photobiomodulation, transcranial near-infrared laser therapy (NILT), or transcranial low level light therapy.
== Medical uses == Elagolix is used in the treatment of moderate to severe pain associated with endometriosis in premenopausal women. Endometriosis is a condition in which the endometrium, the inner lining of the uterus, grows outside of the uterus into surrounding tissues and causes symptoms such as pelvic pain and infertility. Around 10% of women may be affected by endometriosis. Elagolix significantly decreases symptoms of dysmenorrhea (menstrual pelvic pain), non-menstrual pelvic pain, and dyspareunia (pain during sexual intercourse) in women with endometriosis. The medication is used at a lower dosage of 150 mg once per day or at a higher dosage of 200 mg twice per day, depending on the severity of symptoms. The effectiveness of elagolix in the treatment of symptoms of endometriosis was demonstrated in the 6-month Elaris Endometriosis I and II (EM-I and EM-II) phase III clinical trials. In Elaris EM-I, the percentage of women who had a clinical response with respect to dysmenorrhea was 46.4% in the lower-dose elagolix group and 75.8% in the higher-dose elagolix group, as compared with 19.6% in the placebo group; in Elaris EM-II, the corresponding percentages were 43.4% and 72.4%, as compared with 22.7% (P < 0.001 for all comparisons).
Low-velocity: Less than 335 m/s (1,100 ft/s) Low velocity wounds are typical of small caliber handguns. They do not usually cause extensive soft tissue damage, and in the Gustilo open fracture classification are classified as Type 1 or 2 wounds.
Sources: en.wikipedia.org
Another advantage is the accuracy of the method. In an analysis performed by Li et al., it was found that use of fluorescence detection techniques yielded 100% detection accuracy in 13 of 15 collected images. The remaining two had relative errors around 6%. Another advantage of fluorescence detection is that it allows for quantitative analysis of droplet spacing in a sample. This is done by use of temporal measurements and the flow velocity of the analyte. The time spacing between signals allows for calculation of droplet spacing. Further fluorescence analysis of microfluidic droplet samples can be used to measure the fluorescent lifetime of samples, providing additional information that is not obtainable for fluorescence intensity measurements alone. The applications of fluorescence detection are varied, with many of its uses centered in biological applications. Frenz et al. utilized fluorescence detection of droplets to examine enzyme kinetics. For this experiment, b-lactamase interacted with fluorocillin, a fluorogenic substrate. Fluorescence of the droplets was measured at multiple time intervals to examine the change with time. This detection method goes beyond biological applications, though, and allows for the physical study of droplet formation and evolution. For example, Sakai et al. used fluorescence detection to monitor droplet size. This was done by collecting fluorescence data to calculate the concentration of a fluorescent dye within a single droplet, thus allowing size growth to be monitored.
=== Metrology for VOC measurements === To achieve comparability of VOC measurements, reference standards traceable to SI units are required. For a number of VOCs gaseous reference standards are available from specialty gas suppliers or national metrology institutes, either in the form of cylinders or dynamic generation methods. However, for many VOCs, such as oxygenated VOCs, monoterpenes, or formaldehyde, no standards are available at the appropriate amount of fraction due to the chemical reactivity or adsorption of these molecules. Currently, several national metrology institutes are working on the lacking standard gas mixtures at trace level concentration, minimising adsorption processes, and improving the zero gas. The final scopes are for the traceability and the long-term stability of the standard gases to be in accordance with the data quality objectives (DQO, maximum uncertainty of 20% in this case) required by the WMO/GAW program.
This process involves the strategic addition of second-phase particles within a ceramic matrix, optimizing their shape, size, and distribution to direct and control crack propagation. This approach enhances fracture toughness, paving the way for the creation of advanced, high-performance ceramics in various industries.
=== Workforce === CMS employs over 6,000 people, of whom about 4,000 are located at its headquarters in Woodlawn, Maryland. The remaining employees are located in the Hubert H. Humphrey Building in Washington, D.C., the 10 regional offices listed below, and in various field offices located throughout the United States. The head of CMS is the administrator of the Centers for Medicare & Medicaid Services. The position is appointed by the president and confirmed by the Senate. On May 27, 2021, Chiquita Brooks-LaSure was sworn in as administrator, the first black woman to serve in the role.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.